GlassScriptPhysician profile
Fredrick C Hayek
NPI 1982722245
$6,309.60
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $999 · 2021: $1,559 · 2022: $1,241 · 2023: $774 · 2024: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.39 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $968.23 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $907.38 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $897.27 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $745.04 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $398.62 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $269.49 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $238.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $227.87 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.16 | 2019-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $167.45 | 2019-2021 | |
| Lilly USA, LLC | $155.78 | 2019-2024 | Mounjaro |
| Allergan, INC. | $151.92 | 2019-2020 | |
| Almatica Pharma LLC | $144.23 | 2021-2024 | Loreev Xr |
| Novo Nordisk INC | $121.18 | 2019-2023 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $107.44 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $71.76 | 2020-2023 | Eliquis |
| Xeris Pharmaceuticals, INC. | $63.69 | 2022-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $59.67 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $54.39 | 2019-2021 | |
| Shield Therapeutics INC | $52.33 | 2022 | |
| Abbvie INC. | $45.46 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.63 | 2022 | |
| Abbott Laboratories | $34.15 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $34.04 | 2020-2021 | |
| Horizon Therapeutics Plc | $27.25 | 2023 | Krystexxa |
| Genentech USA, INC. | $19.85 | 2022 | |
| Eisai INC. | $16.81 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.36 | 2023 | Quviviq |
| Seqirus USA INC | $15.10 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.00 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.23 | 2022 | |
| Dexcom, INC. | $13.60 | 2023 | Dexcom G6 Transmitter |
| Evoke Pharma, INC. | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredrick Hayek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.